Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluticasone
Drug ID BADD_D00945
Description Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965].
Indications and Usage Fluticasone's 2 esters are indicated as inhalers for the treatment and management of asthma by prophylaxis[FDA Label][F4364]as well as inflammatory and pruritic dermatoses[F4355]. A [DB00588] nasal spray is indicated for managing nonallergic rhinitis[F4358] while the [DB08906] nasal spray is indicated for treating season and perennial allergic rhinitis[F4361,A177130].
Marketing Status approved; experimental
ATC Code D07AC17; R01AD08; R03BA05
DrugBank ID DB13867
KEGG ID D07981
MeSH ID D000068298
PubChem ID 5311101
TTD Drug ID D0LC6K
NDC Product Code 61919-004; 61919-620; 61919-611
UNII CUT2W21N7U
Synonyms Fluticasone | Flonase | Flovent HFA | HFA, Flovent | Cutivate | Fluticasone Propionate | Propionate, Fluticasone | Flixonase | Flixotide | Flovent
Chemical Information
Molecular Formula C22H27F3O4S
CAS Registry Number 90566-53-3
SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Laryngeal pain22.12.03.010--
Laryngitis22.07.03.001; 11.01.13.001--
Leukoderma23.05.02.001--Not Available
Leukopenia01.02.02.001--Not Available
Malaise08.01.01.003--
Migraine24.03.05.003; 17.14.02.001--Not Available
Miliaria23.02.03.014--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle injury12.01.07.002; 15.05.07.001--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Nasal congestion22.04.04.001--
Nasal dryness22.04.03.002--Not Available
Nasal septal operation25.05.03.004--Not Available
Nasal septum perforation22.04.03.003--Not Available
Nasal ulcer22.04.03.011--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Oesophageal candidiasis11.03.03.008; 07.19.06.001--Not Available
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Oral discomfort07.05.05.001--Not Available
Oropharyngeal swelling23.04.01.013; 10.01.05.014; 22.04.05.005; 07.05.04.002--Not Available
Osteoporosis15.02.03.002; 14.04.04.002--
Pain08.01.08.004--
Pain of skin23.03.03.003--
Palpitations02.11.04.012--
Paralysis17.01.04.004--Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages